This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Stay vigilant for fake initial coin offerings by examining whitepapers, token metrics, and regulatory disclosures to prevent losses.
17,900 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Two chipmakers lit up the market in the first half of 2026, but the big question remains: which is the smarter buy no...
As the AI memory crunch enters its second year, three ETFs map different angles of the supply squeeze—from DRAM to br...
Brookfield Asset Management is expanding its AI infrastructure pact with Bloom Energy to $25 billion, signaling a maj...
A new, Lubin-backed nonprofit launches to accelerate institutional adoption of Ethereum and its Layer 2 ecosystem. Th...
BYD again proves it can set records, this time overseas. The question for investors is how long that momentum lasts a...
Investors are buzzing about United States Antimony as shipments update boosts sentiment. This article breaks down the...
Bitcoin rose above $60,000, yet a large inflow of BTC to exchanges suggests the rebound could face renewed selling pr...
A Brixton bank branch faced a bold scam when a man wore an old G4S uniform to obtain cash. This is how the asked cash...
Memory demand tied to AI and data centers has Micron at a pivotal moment. This guide breaks down whether micron stock...
As the energy transition unfolds, two giants stand out: Chevron and Exxon Mobil. This guide breaks down which stock m...
A Montana resident lost tens of thousands online, illustrating how fast a scam can drain savings. This guide breaks d...